ESMO 2023 | Novel drug toxicities in immunotherapy, TKIs and CAR-T

Lazar Popovic, MD, PhD, University of Novi Sad, Novi Sad, Serbia, provides an overview of his talk on novel drug toxicities, which is split into three sections: toxicities of combinations of novel immunotherapies and tyrosine kinase inhibitors, antibody-drug conjugates and of CAR-T based therapies. Specific challenges related to immunotherapy and tyrosine kinase inhibitors are that many of the toxicities are similar, meaning identification of the causative agent can be tricky. In antibody-drug conjugates, detection of trastuzumab deruxtecan-derived interstitial lung disease is essential as well as consideration of the prominent novel drug enfortumab vedotin. Cytokine release syndrome can be associated with CAR-T therapies and, again, its detection proves imperative in the clinical setting. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.